Skip to main content

Market Overview

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Eli Lilly And Co (NYSE: LLY) received an upgrade from a Mizuho Securities analyst ahead of a key data readout in March.

The Lilly Analyst: Vamil Divan upgraded Lilly shares from Neutral to Buy and increased the price target from $164 to $222.

The Lilly Thesis: Lilly has navigated through a catalyst-heavy period and macroeconomic uncertainties that were mainly related to the U.S. presidential election, Divan said in a note.

Added to that, the company impressed with the initial top-line data from its Alzheimer's antibody donanemab, which was released last week, the analyst said.

Mizuho sees the potential for the drug to add significant upside to the Lilly story. 

Lilly has not only potentially found an effective drug, but also understood how to properly design its clinical trials to demonstrate that effect in the right patient population, Divan said. 

The fact that Lilly was able to generate statistically significant results on the primary endpoint in a relatively small trial bodes well for the absolute differences when the full data is released, as well as the clinical meaningfulness of those results, the analyst said.

The full data is set to be released March 13 at the 2021 International Congress on Alzheimer's and Parkinson's Disease, he said.

Related Link: The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications

The Lilly story is already robust with multiple recent positive developments in the areas of diabetes and oncology, Divan said.

Additionally, there are a number of additional pipeline data releases this year, including pivotal data from lebrikizumab and mirikizumab and additional clinical data from tirzepatide and Jardiance, the analyst said.

Since expectations from these data releases, especially lebrikizumab and mirikizumab, aren't too high, Divan sees the possibility for further upside.

Lilly is also expected to release additional Phase 2 Alzheimer's data from its tau antibody zagotenemab, the analyst said.

LLY Price Action: At last check, Lilly shares were rallying 3.99% to $198.43.

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

Latest Ratings for LLY

Mar 2021Truist SecuritiesMaintainsBuy
Feb 2021Cowen & Co.MaintainsOutperform
Feb 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: Mizuho Securities Vamil DivanAnalyst Color Biotech Upgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at